Skip to content

Call Us Today: 812-689-0791

info@neuraxis.com

812-689-0791

info@neuraxis.com

NeurAxis
NeurAxis
  • Home
  • Products
    • IB-Stim
    • RED
  • About
    • About NeurAxis
    • Our Team
    • Patents
  • Investor Relations
  • Contact
  • Home
  • Products
    • IB-Stim
    • RED
  • About
    • About NeurAxis
    • Our Team
    • Patents
  • Investor Relations
  • Contact

PENFS

42 items

  • Press Release

    October 22, 2024

    NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation

    CARMEL, Ind., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE

    Continue reading
  • Press Release

    September 19, 2024

    NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

    CARMEL, Ind., Sept. 19, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE

    Continue reading
  • Press Release

    August 27, 2024

    NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024

    CARMEL, Ind., Aug. 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE

    Continue reading
  • Press Release

    August 13, 2024

    NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024

    CARMEL, Ind., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE

    Continue reading
  • Press Release

    August 9, 2024

    NeurAxis Reports Second Quarter 2024 Financial Results

    Conference call will be held today, Friday, August 9 at 9:00 am ET Carmel, Ind.,

    Continue reading
  • Press Release

    August 5, 2024

    NeurAxis to Host Second Quarter 2024 Results and Business Update Call on Friday, August 9, 2024

    CARMEL, Ind., Aug. 05, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE

    Continue reading
  • Press Release

    June 7, 2024

    NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure

    CARMEL, Ind., June 07, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE

    Continue reading
  • Press Release

    May 22, 2024

    NeurAxis Reports First Quarter 2024 Financial Results

    CARMEL, Ind., May 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE

    Continue reading
  • Press Release

    May 21, 2024

    NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

    CARMEL, Ind., May 21, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE

    Continue reading
  • Press Release

    May 16, 2024

    NeurAxis Announces New Medical Policy Coverage For Nearly Six Million Lives in Florida

    CARMEL, Ind., May 16, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE

    Continue reading
Previous234Next
NeurAxis
(812) 689-0791
info@neuraxis.com

Quick Links

  • Home
  • IB-Stim
  • RED
  • Investor Relations
  • Home
  • IB-Stim
  • RED
  • Investor Relations

About NeurAxis

  • About
  • Our Team
  • Patents
  • Contact Us
  • About
  • Our Team
  • Patents
  • Contact Us

Sign up for News

© 2025 NeurAxis, Inc.  |  All Rights Reserved  |  Privacy & Terms
© 2025 NeurAxis, Inc.  |  All Rights Reserved  |  Privacy & Terms
Page load link
Go to Top